While states continue to lift their COVID related states of emergency, new price gouging claims are being made and ongoing price gouging litigation continues to wind through the courts. The federal government also now...more
On July 11, 2022, the United States District Court for the District of Kansas approved a $264 million settlement against Mylan and certain of its subsidiaries in the case In Re EpiPen (Epinephrine Injection, USP) Marketing,...more
7/29/2022
/ Anti-Competitive ,
Bribery ,
Class Action ,
Kickbacks ,
Motion to Dismiss ,
Mylan Pharmaceuticals ,
Patents ,
Pfizer ,
Pharmaceutical Industry ,
Price Gouging ,
RICO ,
Settlement ,
Sherman Act